Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nanopath

Explore full profile

A molecular diagnostics company disrupting traditional testing methodologies

Cambridge, United StatesFounded 2019Biotech & Life Sciences
Valuation $50–100M Last recorded · 2022
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nanopath and the history behind them.

About Nanopath

Nanopath is a pioneering startup in the field of molecular diagnostics, with a specific focus on women's health. The company aims to revolutionize traditional testing methods by providing detailed and actionable health information within a single office visit. This approach is designed to address the often overlooked complexities of female biology and the emerging healthcare models.

Nanopath operates in the healthcare market, specifically in the molecular diagnostics sector. Its primary clients are healthcare providers who require accurate and rapid diagnostic information for their patients, particularly women. The company's business model is centered around the development and commercialization of its novel diagnostic technologies. It generates revenue through the sale of these technologies to healthcare providers and institutions.

The company was founded as a spin-off from the Thayer School of Engineering at Dartmouth, in partnership with Dartmouth Hitchcock Medical Center. Nanopath's technology platform is designed to detect viral, bacterial, and fungal pathogens without the need for nucleic acid amplification, a process that makes the DNA in a sample easier to detect. While the company's initial focus is on women's infectious diseases, the technology has potential applications beyond this area.

In summary, Nanopath is a healthcare technology startup that aims to improve women's health by providing more accurate and actionable diagnostic information. The company envisions its platform as the go-to system for routine women's health screening at the point-of-care.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Cambridge, United States
Employees
29
Open positions
5
Dealroom signal
86.3/100
Industry
Health, Wellness Beauty
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Marketplace & ecommerce
Client focus
b2b, b2c

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Aug 2026 $200K — MassVentures ↗
GRANT✓Other financing May 2024 $4M — US National Science Foundation · National Institutes of Health ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Nanopath website traffic

Latest recorded traffic for Nanopath is 460 monthly website visits, down 96.2% over the last three months. Nanopath's team grew 26.1% over the past year.

Latest monthly visits460 3-month web change-96.2% 1-year team growth+26.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • US National Science Foundation
  • National Institutes of Health
  • MassVentures

Series A4 investors entered at this stage

Other known investors4 additional known investors

  • Dartmouth College
  • Alumni Ventures
  • Creative Destruction Lab
  • Undeterred Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nanopath on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nanopath’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.